Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

53
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
53
One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance00:56

One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance

173
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
173
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

78
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
78

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein(a), Cholesterol, Triglyceride Levels, and Vulnerable Coronary Plaques: A PROSPECT II Substudy.

Journal of the American College of Cardiology·2025
Same author

Impact of Optical Coherence Tomography-Based Post-PCI Physiology Assessment to Predict Clinical Outcomes: An ILUMIEN-IV Substudy.

Journal of the American College of Cardiology·2025
Same author

Safety and Efficacy of Cobalt Chromium Everolimus-Eluting Stents for Treatment of In-Stent Restenosis: An ILUMIEN IV Substudy.

Journal of the American Heart Association·2025
Same author

Stent-Edge Hinge Movement in a Calcified Lesion Is Associated With Increased Prevalence of a Calcified Nodule at Follow-Up.

Circulation. Cardiovascular interventions·2025
Same author

Factors Associated With Chronic Stent Recoil and its Impact on Revascularization: A Serial Optical Coherence Tomography Study.

JACC. Cardiovascular interventions·2025
Same author

Relationships of hsCRP to High-Risk Vulnerable Plaque After NSTEMI: Insights From the PROSPECT II Trial.

JACC. Cardiovascular interventions·2025

Related Experiment Video

Updated: Oct 25, 2025

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

1.7K

Stent Expansion Indexes to Predict Clinical Outcomes: An IVUS Substudy From ADAPT-DES.

Tatsuhiro Fujimura1, Mitsuaki Matsumura2, Bernhard Witzenbichler3

  • 1Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA.

JACC. Cardiovascular Interventions
|August 6, 2021
PubMed
Summary

Relative stent expansion, measured as stent/vessel area at minimum stent area (MSA) site, better predicts adverse events after percutaneous coronary intervention (PCI) than absolute MSA. This finding aids in optimizing stent placement for improved patient outcomes.

Keywords:
drug-eluting stent(s)intravascular ultrasoundmajor adverse cardiac event(s)minimum stent areapercutaneous coronary intervention

More Related Videos

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

14.0K

Related Experiment Videos

Last Updated: Oct 25, 2025

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

1.7K
Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

14.0K

Area of Science:

  • Cardiovascular Interventions
  • Medical Imaging
  • Biomedical Engineering

Background:

  • Intravascular ultrasound (IVUS) studies consistently identify minimum stent area (MSA) as a key predictor of future cardiovascular events.
  • Optimizing stent deployment is crucial for successful percutaneous coronary intervention (PCI).

Purpose of the Study:

  • To evaluate diverse stent expansion indexes for their predictive capability of clinical outcomes.
  • To identify the most effective index for assessing stent deployment success in drug-eluting stent (DES) procedures.

Main Methods:

  • Analysis of a prospective, multicenter registry (ADAPT-DES) of 8,582 patients undergoing PCI with DES.
  • Inclusion of 2,140 lesions treated with IVUS-guided PCI, assessing ten stent expansion indexes.
  • Evaluation of associations between indexes and 2-year rates of clinically driven target lesion revascularization (TLR) or definite stent thrombosis.

Main Results:

  • The final mean MSA was 6.2 ± 2.4 mm² across 2,140 lesions.
  • Only the stent/vessel area at the MSA site independently predicted 2-year TLR or definite stent thrombosis (HR: 0.77; 95% CI: 0.59-0.99; P=0.04).
  • This relative expansion index outperformed absolute MSA and other evaluated metrics.

Conclusions:

  • In IVUS-guided PCI with good overall MSA, stent/vessel area at the MSA site is a superior predictor of adverse outcomes.
  • Relative stent expansion is more valuable than absolute measurements for predicting long-term clinical events after DES implantation.